Wells Fargo added Annexon to the firm’s Q4 2024 Tactical Ideas List, while keeping an Overweight rating on the shares with a price target of $14. The firm believes shares remain undervalued given ANX005’s positive Phase 3 data in Guillain-Barre syndrome and the risk/reward is skewed to the upside ahead of ANX1502’s proof-of-concept trial in cold agglutinin disease and IGOS data in GBS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANNX: